Section A-Research Paper
ISSN 2063-5346

Drug Discovery and Design: Computational Approaches and Structure-Activity Relationship Studies

***Brij Kishore Tiwari, ** Pranshul Sethi, ***Khushboo Shrimali, ****Vishnu Das,**

*******Tanu Chaudhary, ******Nilesh Kumar Upadhyay**

*Assistant Professor, Department of Applied Sciences, G L Bajaj Institute of Technology and Management, Greater Noida, U.P., India, Email: brijktiwari01@gmail.com

**Assistant Professor, Department of Pharmaceutical Sciences, Lingaya's University, Faridabad, Haryana, India, Email: pranshul.sethi19@gmail.com

***Research Scholar, Department of Pharmaceutical Sciences, B.N.University, Udaipur, Rajasthan, India, Email: khushbooshrimali@gmail.com

****Research Scholar, Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, Udaipur, Rajasthan, India, Email: vishnudas1111@gmail.com

***** Assistant Professor, Department of Pharmaceutical Sciences, Lingaya's University, Faridabad, Haryana, India, Email: chaudharytanu26may@gmail.com

******Assistant Professor, Department of Pharmacy, Smt. Fulehra Smarak College of Pharmacy, Rasra, Ballia, U.P., India, Email: nileshupadhyay827@gmail.com

Abstract

Drug discovery using computational methods has gained momentum in recent years, offering novel approaches to address complex healthcare challenges. However, this field also faces various challenges, including data quality, model accuracy, and the complexity of biological systems. Additionally, computational cost and polypharmacology remain critical issues. Nonetheless, exciting future perspectives offer promising solutions. Integration of multi-omics data, artificial intelligence applications, and personalized medicine advancements provide opportunities to enhance drug discovery efficiency. Furthermore, incorporating quantum mechanics in drug design and leveraging cloud computing and high-performance resources hold transformative potential. These advancements pave the way for revolutionizing drug discovery and improving treatment efficacy, fostering better healthcare outcomes for patients worldwide.

KEYWORDS:Drug discovery, Computational methods, Healthcare challenges, Data quality, Model accuracy, Biological systems

1. Drug Discovery and Design

A medication is a non-natural molecule which impacts biological processes and also get utilized to treat, diagnose, or prevent disease. Drugs may get produced synthetically or naturally. The optimum drug should have a specific effect, be non-toxic and secure, chemically and metabolically stable, with no side effects or as few as possible, synthetically feasible, soluble in water at therapeutic concentrations to prevent precipitation in the blood stream, soluble in lipids as well to be able to cross lipid membranes and distribute throughout the body, and ultimately, be a

unique molecule [1]. New medications were the main focus of clinical research while developing new drugs for chronic diseases. Recently, a number of medications have been developed that can distinguish between dynamic components from conventional treatments like penicillin. It is composed of natural chemicals and tiny molecules which are implemented in chemical laboratories to aid in the detection of cells or whole organisms for medicinal purposes. Old-style pharmacology [2] is the term for this process. The basis of contemporary drug discovery programs is data and the growing use of prediction models, comprising of machine as well as deep learning [3]. Finding drug candidates is becoming less expensive and time-consuming thanks to the growing use of computational techniques, which recently incorporated deep learning [4]. In this case, more than 70 authorized drugs, including remdesivir, have been found by means of computer-aided drug design (CADD) [5], which will be utilised as an urgent treatment for SARS-CoV-2 in 2021 [6].

2. Overview of Computational Approaches in Drug Discovery

The idea of computer-aided drug discovery originated in the 1970s and made popular by Fortune magazine in 1981. Since then, there have been multiple cycles of hype and delusion surrounding the idea. There have been some notable successes along the road, and generally speaking, computer-assisted methods are now an essential, if modest, component of the drug development process. But in recent years, a number of scientific and technological developments have brought about a tectonic shift toward the acceptance of computational methodologies as an essential driving component for drug discovery in both business along with academia. Businesses in the pharmaceutical and biotech industries are either recruiting their first computational chemists or expanding their use of computational approaches for drug discovery. In the recent years, a number of novel and established drug discovery enterprises have generated billions [7] with business models that primarily depend on the fusion of reliable artificial intelligence (AI) as well as physics-based molecular modeling with deep learning (DL).



Fig.1 Machine Learning in Drug Discovery and Development

In the drug discovery and development process, machine learning plays a pivotal role through various stages, as shown in figure 1. Data collection involves gathering relevant biological, chemical, and pharmacological data from diverse sources. The collected data then undergoes preprocessing to ensure consistency and quality. Feature selection/extraction identifies essential features crucial for drug discovery and development. For model selection, appropriate machine learning models are chosen based on the specific problem. These selected models undergo training using preprocessed data to learn patterns and relationships. Validation and performance evaluation assess model performance using metrics through cross-validation. Model optimization fine-tunes hyperparameters to achieve better performance and generalization. Virtual screening predicts the activity of new compounds, prioritizing potential drug candidates. Lead optimization utilizes machine learning to optimize interactions and properties of lead compounds. ADMET prediction involves employing models to predict compound properties relevant to absorption, distribution, metabolism, excretion, and toxicity. Clinical trials prediction helps foresee drug candidates' success and safety during clinical trials. Drug repurposing identifies existing drugs with potential new indications. De novo drug design generates new drug-like compounds with desired properties. Safety assessment predicts potential adverse drug reactions, prioritizing safety assessment. Drug-drug interaction prediction identifies

potential interactions and assesses their impact. Biomarker discovery employs machine learning to identify and validate disease biomarkers. Optimizing clinical trials involves using predictive modeling to optimize trial design and patient recruitment. Regulatory compliance ensures adherence to guidelines and ethical considerations. Deployment and integration entail implementing successful machine learning models into drug discovery pipelines. Continuous learning and improvement involve updating and refining models with new data to adapt to scientific advancements, fostering a dynamic and cutting-edge drug discovery landscape.

Computer-aided drug design (CADD) techniques are vital for the cost-effective identification of feasible therapeutic candidates and considerably facilitate drug discovery. Through the drug discovery process, these computational techniques help medicinal chemists and pharmacologists by alleviating the usage of animal models in pharmacological research, repositioning already-marketed medications, along with assisting in the rational design of novel and safe drug candidates [8Leading pharmaceutical corporations and research groups are accelerating the drug discovery and development process while reducing costs and failures in the final stage by utilizing computer-aided drug discovery (CADD) approaches in early research [9]. To better understand the binding affinity and molecular interaction between the target protein and the ligand, rational drug design—a vital component of CADD—offers illuminating information. The advancement of parallel processing, advanced algorithms, tools, and programs, as well as supercomputing facilities, has made lead discovery in pharmaceutical research easier [10].

Computational approaches are successful strategies in the drug discovery and development process, and computational methods and tools have evolved enormously in recent decades due to the substantially increased availability of computational resources [11].

3. Molecular Docking and Virtual Screening Techniques

a) Virtual screening (VS)

Utilizing computer-aided drug design (CADD), sometimes referred to as molecular modeling, is one technique that alleviates restrictions on drug development and manufacturing while minimizing cost and time impacts. In such a method, the drug design and analysis phases are completed taking the usage of a cyclic-assisted process that is totally carried out by in silico simulations. These approaches of simulation might evaluate key drug development factors like activity, toxicity, bioavailability, as well as biological activity even before undertaking in vitro and in vivo clinical trials [12].The International Union of Pure and Applied Chemistry (IUPAC) asserts that VS have demonstrated to be computational techniques that classify molecules in a database based on their tendency to exhibit biological characteristics against a certain molecular target [13].In the CADD method's virtual screening (VS) stage, virtual compound libraries have been screened. VS is a technique for classifying molecules based on biological or chemical features observed in significant datasets.



Fig. 2Virtual screening process [13].

b) Molecular docking

Molecular docking is an approach that examines the shape and orientation of molecules as they enter the binding site of a macromolecular target (referred to collectively as the "pose"). Poses that might be taken are generated by search algorithms, and scoring functions score them [14]. To easily obtain the structures of these macromolecules, use the Protein Data Bank (PDB), that provides access to 3D atomic coordinates discovered through experimental techniques. The experimental 3D structure of the target has become occasionally unavailable, though, so this is not unusual. Computing prediction techniques, like comparative and ab initio modeling, which are utilized for estimation of the 3D structure of proteins, can be used to resolve this issue [14].



Fig. 3 A classical structure-based drug design (SBDD) approach [15]

Molecular docking is the approach utilised most frequently in SBDD. The process of fine-tuning a model of a complicated framework by increasing the separation between partners while maintaining stable relative orientations was originally referred to as "docking," and it was first utilized in the late 1970s. Later, although enabling the internal geometry of each partner to change, the relative orientation remained constant. Rigid docking is a term that is frequently used to describe this kind of modeling [15]. In silico structure-based molecular docking is a well-known technology that is frequently employed in drug development, according to Pinzi, L., et al., (2019) [16]. It is possible to define structure-activity relationships (SAR), anticipate ligand-target interactions at the molecular level, and find new therapeutic compounds via docking without first knowing the chemical make-up of other target modulators. Docking was initially emerged to aid in the understanding of the mechanics of molecular recognition between small and large molecules, but in recent years, its applications in drug discovery have undergone a considerable shift. In their article, the scientists described how molecular docking was initially employed for tasks related to drug discovery. After that, they demonstrated some more recent and advanced docking uses and applications, such as profiling, drug repurposing, target fishing, polypharmacology, as well as the prediction of negative effects. Furthermore, they discussed prospective uses in the future as well as the method's continued evolution in light of the use of more advanced techniques like artificial intelligence.

4. Discovery of drugs of the future

Latest medications have typically been found by testing a large number of synthetic chemical compounds or natural products for intended effects. Although this method of developing novel pharmacological medicines has been successful previously, there are a number of reasons why it is not the optimum. The need for a competent screening approach is the screening approach's biggest drawback. It is and time-consuming as well as repetitive even to locate a molecule with the desired activity because of the inherent unpredictability of the screening method. Drugs can be precisely developed to interact with the target molecule in a way that is helpful in disease disruption after the disease process is understood at the molecular level and the target molecule (s) is established. Due to the huge

quantity of data that must be accumulated in order to produce medications using this strategy, this is the area where computer-aided drug design will have the biggest influence [17].

5. Case Studies and Applications of Computational Approaches in Drug Discovery

The frequency of drug recalls has elevated most recently, according to **Wu, F et al. (2020) [18]**, which has caused pharmaceutical corporations to pay greater attention to the preclinical medications' safety assessment. Despite the fact that these technologies are expensive, in vitro and in vivo drug assessment approaches are today more well-established in preclinical applications. The use of in silico technology to assess the pertinent features of medications in the preclinical stage has elevated significantly in past years because of the promptdevelopment of computer science. The research of ADMET in vitro has been further stimulated as an outcome of the development of numerous software programs and in silico models. Molecular modeling and data modeling are the two types of ADMET prediction we first cover in this review. After that, they organized the classification and description of the databases and algorithms that are frequently taken into usage for ADMET prediction. The researchers concentrated on some of the extensively researched ADMT properties and PBPK simulation, and they mentioned some associated applications for the prediction categories and online resources. Finally, they talked about the difficulties and restrictions that exist in the preclinical field and offer some recommendations and future prospects.

One of the crucial steps in the pharmaceutical sector is the development of new drugs. The time and expense involved in finding new drugs have been significantly decreased by various computational techniques. The first part of Lin, X., et al.'s work (2020) [19] examined the functions of multiscalebiomolecular simulations in identifying drug binding sites on the target macromolecule and delineating drug action mechanisms. Then, structure- and ligand-based classical/de novo drug design was introduced. Additionally included were virtual screening techniques such molecular docking, pharmacophore modeling, and QSAR. Finally, they looked at how machine learning techniques are being developed and how they might be taken into usagefor acceleration of the drug discovery process in the aforementioned computational methodologies.It was also explored how different approaches could be combined in various applications. Inevitably, the future of drug screening and design will involve combining several approaches to collaboratively tackle challenging problems at many scales and dimensions.

A long-standing obstacle to future scientific advancement is the reproducibility of experiments. Because they may be used in a variety of ways for data collecting, pre-processing, analysis, and inference, computational approaches have played a crucial role in drug development efforts. The consistency of computational drug discovery is thoroughly covered in this paper. The following are some of the topics covered by Schaduangrat, N. et al. (2020) [20]: (1) The state of reproducible research at the moment; (2) Research documentation (e.g., Jupyter notebooks; electronic laboratory notebooks); (3) Model development in computational drug discovery; (4) Computational issues on Model Development and Deployment; (5) The science of reproducible research (i.e., comparison and contrast with related concepts such as reusability, reliability, as well as replicability); and (6) Use Case Scenarios for accelerating Computational Drug Discovery, Sharing data and programming codes utilised for numerical calculations has become a regular practice for promoting collaborations and reproducibility (i.e., for extending the project by adding new concepts, increasing the data, upgrading the code, etc.).As a result, the field of computational drug design will unavoidably embrace an open strategy for gathering, protecting, and sharing data/code.

6. Machine Learning and Artificial Intelligence in Drug Discovery

Drug and biopharmaceutical companies, which lacked access to cutting-edge and revolutionary technologies or equipment, have been the driving force behind the development of unique concepts or interpretations in fundamental mechanical and chemical engineering. The pharmaceutical sector need to immediately prioritize mechanical innovation to make it simpler to produce medications for human use. It has been challenging to develop novel medications that are safe for people on a commercial scale and to put them into widespread therapeutic usage because of the present constraints on technological resources [21].According to Paul D et al. (2020) [22], the usage of artificial intelligence (AI) has elevated in a variety of socioeconomic areas, notably the pharmaceutical industry. In theirwork, the authors concentrated on the use of AI in many pharmaceutical industry domains, including drug

development and discovery, drug repurposing, boosting clinical trials, as well aspharmaceutical productivity, among others. This application of AI accelerates the goal-achieving while reducing the workload of human labor. The researchers discussed the future of AI in the pharmaceutical sector as well as how distinct AI tools and approaches interact, as well as present challenges and possible solutions.

7. Challenges and Future Perspectives in Drug Design using Computational Methods

The field of drug design using computational methods presents both challenges and promising future perspectives. One of the primary challenges lies in ensuring the quality and accessibility of data, which directly impacts the reliability of computational predictions. Additionally, achieving high model accuracy and validation against experimental data remains crucial to build trust in computational approaches. The complexity of biological systems poses another hurdle, as accurately modeling intricate interactions demands sophisticated algorithms and extensive computational resources. Moreover, the computational cost and time required for large-scale simulations and virtual screening can be limiting factors. Addressing polypharmacology, where drugs interact with multiple targets, requires advanced methods to predict off-target effects and potential side effects accurately. On the bright side, future perspectives offer exciting solutions. Integrating multi-omics data provides a more comprehensive understanding of disease mechanisms, enabling better target identification and validation. The application of artificial intelligence can accelerate drug discovery processes, enhancing virtual screening and predicting drug-target interactions with higher accuracy. Advancements in personalized medicine hold potential for tailored treatments based on individual patients' genetic and molecular profiles. Incorporating quantum mechanics in drug design promises more precise insights into molecular interactions, especially for challenging cases. Furthermore, leveraging cloud computing and high-performance resources allows researchers to access powerful computational tools, driving progress in drug discovery. In conclusion, overcoming challenges and embracing future perspectives will revolutionize drug design, leading to more efficient and effective approaches for improved healthcare outcomes.

Conclusion

In conclusion, review exemplifies the pivotal role of computational approaches in advancing the drug discovery field. This review paper has delved into the diverse and innovative approaches employed in drug design, leveraging computational tools to unravel the complexities of molecular interactions and structure-activity relationships. By elucidating the power of computational approaches in rational drug design, the study has paved the way for future research and development in pharmaceutical sciences. The integration of computational techniques has the potential to accelerate the discovery of novel therapeutics, optimize drug candidates, and ultimately lead to the discovery of more efficient and targeted treatments for several diseases. As we embark on a new era of drug discovery, this review serves as an invaluable resource, guiding researchers and pharmaceutical scientists towards groundbreaking discoveries that can transform patient care and improve global healthcare outcomes.

REFERENCES

[1] Doytchinova I. Drug Design-Past, Present, Future. Molecules. 2022 Feb 23;27(5):1496. doi: 10.3390/molecules27051496. PMID: 35268598; PMCID: PMC8911833.

[2] Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine Learning in Drug Discovery: A Review. ArtifIntell Rev. 2022;55(3):1947-1999. doi: 10.1007/s10462-021-10058-4. Epub 2021 Aug 11. PMID: 34393317; PMCID: PMC8356896.

[3] Chávez-Hernández Ana L., López-López Edgar, Medina-Franco José L. Yin-yang in drug discovery: rethinking de novo design and development of predictive models, Frontiers in Drug Discovery, VOLUME=3, YEAR=2023, https://www.frontiersin.org/articles/10.3389/fddsv.2023.1222655 DOI=10.3389/fddsv.2023.1222655

[4] Zhang, Y., Luo, M., Wu, P., Wu, S., Lee, T. Y., and Bai, C. (2022). Application of computational biology and artificial intelligence in drug design. Int. J. Mol. Sci. 23 (21), 13568. doi:10.3390/ijms232113568

[5] Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., et al. (2021). Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur. J. Med. Chem. 224, 113705. doi:10.1016/j.ejmech.2021.113705

[6] Dos Santos Nascimento, I. J., de Aquino, T. M., and da Silva-Júnior, E. F. (2021). Drug repurposing: A strategy for discovering inhibitors against emerging viral infections. Curr. Med. Chem. 28 (15), 2887–2942. doi:10.2174/0929867327666200812215852

[7] Sadybekov, A.V., Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673–685 (2023). https://doi.org/10.1038/s41586-023-05905-z

[8] Brogi, S., Ramalho, T. C., Kuca, K., Medina-Franco, J. L., &Valko, M. (2020). In silico methods for drug design and discovery. Frontiers in chemistry, 8, 612, https://doi.org/10.3389/fchem.2020.00612

[9] Yu, W., MacKerell, A.D. (2017). Computer-Aided Drug Design Methods. In: Sass, P. (eds) Antibiotics. Methods in Molecular Biology, vol 1520. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6634-9_5

[10] Macalino, S.J.Y., Gosu, V., Hong, S. et al. Role of computer-aided drug design in modern drug discovery. Arch. Pharm. Res. 38, 1686–1701 (2015). https://doi.org/10.1007/s12272-015-0640-5

[11] Anshul Tiwari, Sakshi Singh, Chapter 13 - Computational approaches in drug designing, Editor(s): DevBukhsh Singh, Rajesh Kumar Pathak, Bioinformatics, Academic Press, 2022, Pages 207-217, ISBN 9780323897754, https://doi.org/10.1016/B978-0-323-89775-4.00010-9.

[12] Ferreira, R. S., Glaucius, O., &Andricopulo, A. D. (2011). Integrating virtual and high-throughput screening: opportunities and challenges in drug research and development. Química Nova, 34, 1770-1778.

[13] Martin, Yvonne C., Abagyan, Ruben, Ferenczy, György G., Gillet, Val J., Oprea, Tudor I., Ulander, Johan, Winkler, David and Zefirov, Nicolai S.. "Glossary of terms used in computational drug design, part II (IUPAC Recommendations 2015)" Pure and Applied Chemistry, vol. 88, no. 3, 2016, pp. 239-264. https://doi.org/10.1515/pac-2012-1204

[14] Zhifeng Liu, Yujie Liu, Guangming Zeng, Binbin Shao, Ming Chen, Zhigang Li, Yilin Jiang, Yang Liu, Yu Zhang, Hua Zhong, Application of molecular docking for the degradation of organic pollutants in the environmental remediation: A review, Chemosphere, Volume 203, 2018, Pages 139-150, ISSN 0045-6535, https://doi.org/10.1016/j.chemosphere.2018.03.179.

[15] de Ruyck J, Brysbaert G, Blossey R, Lensink M. Molecular docking as a popular tool in drug design, an in silico travel. AdvApplBioinform Chem. 2016;9:1-11 https://doi.org/10.2147/AABC.S105289

[16] Pinzi, L., &Rastelli, G. (2019). Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Sciences, 20(18), 4331. MDPI AG. Retrieved from http://dx.doi.org/10.3390/ijms20184331

[17] Danao, K., Nandurkar, D., Rokde, V., Shivhare, R., & Mahajan, U. (2022). Molecular Docking: Metamorphosis in Drug Discovery. In Molecular Docking-Recent Advances. IntechOpen. DOI: 10.5772/intechopen.105972

[18] Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., ...& Huang, Z. (2020). Computational approaches in preclinical studies on drug discovery and development. Frontiers in chemistry, 8, 726, https://doi.org/10.3389/fchem.2020.00726

[19] Lin, X., Li, X., & Lin, X. (2020). A Review on Applications of Computational Methods in Drug Screening and Design. Molecules, 25(6), 1375. MDPI AG. Retrieved from http://dx.doi.org/10.3390/molecules25061375

[20] Schaduangrat, N., Lampa, S., Simeon, S. et al. Towards reproducible computational drug discovery. J Cheminform 12, 9 (2020). https://doi.org/10.1186/s13321-020-0408-x

[21] JukkaRantanen, Johannes Khinast, The Future of Pharmaceutical Manufacturing Sciences, Journal of Pharmaceutical Sciences, Volume 104, Issue 11, 2015, Pages 3612-3638, ISSN 0022-3549, https://doi.org/10.1002/jps.24594.

[22] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21. PMID: 33099022; PMCID: PMC7577280.